NTRK1 and gastrointestinal stromal tumor: Imatinib is a selective, small molecule inhibitor of three receptor tyrosine kinases: the transmembrane receptor KIT, the chimeric BCR-ABL fusion oncoprotein of chronic myeloid leukemia and PDGFRA. In 2002, the FDA approved imatinib for the management of patients with advanced GIST.